Electronic supplementary information

Molecular hydrogen and water activation by transition metal frustrated Lewis pairs containing ruthenium or osmium components: catalytic hydrogenation assays

Sophie Beard, Alejandro Grasa, Fernando Viguri, Ricardo Rodríguez, José A. López, Fernando J. Lahoz, Pilar García-Orduña, Pilar Lamata,* and Daniel Carmona*

Instituto de Síntesis Química y Catálisis Homogénea (ISQCH), CSIC - Universidad de Zaragoza, Departamento de Química Inorgánica, Pedro Cerbuna 12, 50009 Zaragoza, Spain. E-mail: <u>dcarmona@unizar.es</u>, <u>plamata@unizar.es</u>

Table of Contents

1 Preparation and characterization of the phosphano-thiourea ligand H_2L1	S1
2 Preparation and characterization of the complexes 1-4	S2
3 Kinetic studies for the H/D exchange at the Cym methyl protons of complex 7	S7
4 NMR and DFT studies on the fluxionality of the complexes 5, 6, 11 and 12	S10
5 NMR spectra of the ligand H_2L1 and of the complexes 1-6 and 11-19	S15
6 Catalytic hydrogenation essays	S36
7 X-ray crystallography	S 39
8 Molecular structures of complexes 2, 4, 6 and 14	S44
9 DFT calculations	S50

1 Preparation and characterization of the phosphano-thiourea ligand H₂L1

At RT, a mixture of 2-(diphenylphosphano)ethylamine (1.20 g, 5.23 mmol) and *p*-Tolylisothiocyanate (780.9 mg, 5.23 mmol) in dry THF (10 mL) was stirred for 15 h. The resulting solution was vacuum-evaporated to dryness. The residue was washed with *n*-hexane (3×5 mL). Evaporation of the solvent under vacuum gave the phosphano-thiourea compound as a white solid.



 H_2L1

Yield: 1.93 g, 98 %. Anal. Calcd for $C_{22}H_{23}N_2PS$: C, 69.8; H, 6.1; N, 7.4; S, 8.5 Found: C, 69.55; H, 6.6; N, 7.4; S, 8.4. HRMS (μ -TOF), $C_{22}H_{24}N_2PS$, $[M + H]^+$, calcd: 379.1392, found: 379.1381. IR (cm⁻¹): v(NH) 3319 (br), 3160 (br). ¹H NMR (500.10 MHz, CD₂Cl₂, RT): δ = 7.70 (s, 1H, *p*-TolylN*H*), 7.46-7.32 (m, 10H, PPh₂), 7.22, 7.05 (AB system, *J*(A,B) = 8.0 Hz, 4H, *p*-Tolyl), 6.24 (bs, 1H, N*H*CH₂), 3.74 (m, 2H, NCH₂), 2.41 (m, 2H, PCH₂), 2.36 (s, 3H, Me). ¹³C {¹H} NMR (125.77 MHz, CD₂Cl₂, RT): δ = 181.57 (C=S), 138.65 (d, *J* = 12.6 Hz), 133.54, 133.39, 129.60, 129.36, 129.30 (PPh₂), 138.16 (CN), 134.27 (*C*Me), 131.63 (CH₃, CH₅), 126.44 (CH₂, CH₆) (*p*-Tolyl), 43.34 (d, *J* = 21.23 Hz, CH₂N), 28.93 (CH₂P), 21.86 (Me). ³¹P {¹H} NMR (202.46 MHz, CD₂Cl₂, RT): δ = -21.20 (s).

2 Preparation and characterization of the complexes 1-4

Preparation of the complexes $[(Cym)MCl(\kappa^2S, P-H_2L1)][SbF_6]$ (M= Ru (1), Os(2))

To a suspension of the dimer [{(Cym)MCl}₂(μ -Cl)₂] (0.25 mmol), in methanol (10 mL), 190.0 mg (0.50 mmol) of H₂L1 and 129.9 mg (0.50 mmol) of NaSbF₆ were added. The resulting solution was stirred for 15 h and vacuum-evaporated to dryness. The residue was extracted with dichloromethane and the solution was concentrated under reduced pressure to *ca*. 2 mL. The slow addition of *n*-pentane led to the precipitation of an orange (ruthenium) or yellow (osmium) solid which was washed with *n*-pentane (3 × 5 mL) and vacuum-dried. Crystals of **2** suitable for X-ray diffraction analysis were obtained by crystallisation from CH₂Cl₂/*n*-hexane solutions.



Complex 1. Yield: 407.0 mg, 92 %. Anal. Calcd for $C_{32}H_{37}N_2ClF_6PRuSSb: C, 43.4; H, 4.2; N, 3.2; S, 3.6. Found: C, 43.6; H, 4.1; N, 3.2; S, 3.75. HRMS (<math>\mu$ -TOF), $C_{32}H_{37}N_2ClPRu$, [M – SbF₆]⁺, calcd: 649.1142, found: 649.1126. IR (cm⁻¹): v(NH) 3335 (br), v(SbF₆) 655 (s). ¹H NMR (500.10 MHz, CD₂Cl₂, RT): δ = 8.35 (s, 1H, *p*-TolylN*H*), 7.89-7.48 (m, 10H, PPh₂), 7.26 (bd, J = 7.4, 2H, H₃, H₅, *p*-Tolyl), 6.95 (bs, 2H, H₂, H₆, *p*-Tolyl), 6.56 (bs, 1H, CH₂N*H*), 5.74 (bs, 1H, H_B), 5.59 (bs, 1H, H_A), 5.20 (s, 2H, H_A', H_B'), 3.83 (bs, 1H, NCH₂), 3.43 (m, 1H, NCH₂), 3.02, 2.16 (2 × m, 2H, PCH₂), 2.51 (m, 1H, CH *i*Pr), 2.38 (s, 3H, Me *p*-Tolyl), 1.88 (s, 3H, Me Cym), 1.23 (bs, 3H, Me *i*Pr), 0.95 (bs, 3 H, Me *i*Pr). ¹³C {¹H} NMR (125.77 MHz, CD₂Cl₂, RT): δ = 135.76-129.73 (PPh₂), 131.75 (CH₃, CH₅, *p*-Tolyl), 126.55 (CH₂, CH₆, *p*-Tolyl), 93.92

(CH_A), 91.30 (CH_B), 90.02, 89.19 (CH_{A'}, CH_{B'}), 30.78 (CH *i*Pr), 22.59, 22.07 (Me *i*Pr), 21.66 (Me *p*-Tolyl), 17.85 (Me Cym). ³¹P{¹H} NMR (202.46 MHz, CD₂Cl₂, RT): δ = 23.65 (vbs). ³¹P{¹H} NMR (202.46 MHz, CD₂Cl₂, 173 K): δ = 35.91 (s) major, 19.39 (s) minor.



Complex 2. Yield: 457.8 mg, 94 %. Anal. Calcd for C₃₂H₃₇N₂ClF₆OsPSSb: C, 39.5; H, 3.8; N, 2.9; S, 3.3. Found: C, 39.3; H, 3.9; N, 2.7; S, 3.3. HRMS (μ-TOF), C₃₂H₃₇N₂ClOsPS, [M – SbF₆]⁺, calcd: 739.1702, found: 739.1700. IR (cm⁻¹): v(NH) 3238-3417 (br), v(SbF₆) 659 (s).

Major isomer. ¹H NMR (500.10 MHz, CD₂Cl₂, 193 K): δ = 8.45 (s, 1H, *p*-TolylN*H*), 7.85-7.07 (m, 10H, PPh₂), 7.06 (d, *J* = 7.5 Hz, 2H), 6.48 (d, *J* = 8.3 Hz, 2H, *p*-Tolyl), 6.07 (bs, 1H, CH₂N*H*), 5.77 (d, *J* = 5.6 Hz, 1H, H_B), 5.69 (d, 1H, H_A), 5.07 (d, *J* = 7.6 Hz, 2H, H_A., H_B.), 4.42, 3.42 (2 × m, 2H, NCH₂), 2.90, 2.59 (2 × m, 2H, PCH₂), 2.31 (m, 1H, CH *i*Pr), 2.21, (s, 3H, Me *p*-Tolyl), 1.88 (s, 3H, Me Cym), 1.12 (d, *J* = 6.4 Hz, 3H, Me *i*Pr), 0.85 (d, *J* = 6.1 Hz, 3H, Me *i*Pr). ¹³C{¹H} NMR (125.77 MHz, CD₂Cl₂, 193K): δ = 177.63 (C=S), 135.87 (d, *J* = 55.0), 127.87 (d, *J* = 53.5), 132.29-126.71 (PPh₂), 138.89, 130.72 (CH₃, CH₅, *p*-Tolyl), 130.83, 124.51 (CH₂, CH₆, *p*-Tolyl), 108.73 (*C*-Me, Cym), 94.55 (*C*-*i*Pr, Cym), 85.17 (CH_B), 81.79 (CH_A), 81.34 (CH_B.), 79.73 (CH_A.), 42.80 (CH₂N), 29.14 (CH *i*Pr), 27.72 (d, *J* = 35.8, CH₂P), 21.76, 21.49 (Me *i*Pr), 21.05 (Me *p*-Tolyl), 17.00 (Me Cym). ³¹P{¹H} NMR (202.46 MHz, CD₂Cl₂, 193K): δ = -8.22 (s).

Minor isomer. ¹H NMR (500.10 MHz, CD₂Cl₂, 193 K): *δ* = 8.35 (s, 1H, *p*-TolylN*H*), 7.85-7.07 (m, 10H, PPh₂), 5.69, 5.62, 5.37, 5.20 (4 × bd, 4H, H_A, H_B, H_{A'}, H_{B'}), 3.42, 3.14, 3.05, 2.59

 $(4 \times m, 4H, CH_2CH_2)$, 1.88 (m, 1H, CH *i*Pr), 1.03 (bd, J = 5.3 Hz, 3H, Me *i*Pr), 0.66 (bd = 5.07 Hz, 3H, Me *i*Pr). ¹³C{¹H} NMR (125.77 MHz, CD₂Cl₂, 193K): $\delta = 177.41$ (C=S), 140.08, 130.47 (*p*-Tolyl), 103.42, 93.31 (*C*-Me, *C*-*i*Pr, Cym), 84.79, 82.88, 78.92, 77.89 (CH_A, CH_B, CH_A, CH_B), 39.76 (CH₂N), 28.54 (CH *i*Pr), 21.85, 21.24 (Me *i*Pr). ³¹P{¹H} NMR (202.46 MHz, CD₂Cl₂, 193K): $\delta = -23.84$ (s).

³¹P{¹H} NMR (202.46 MHz, CD₂Cl₂, RT): $\delta = -16.50$ (s).

Preparation of the complexes
$$[(Cym)M(\kappa^3S,P,N-H_2L1)][SbF_6]_2$$
 (M= Ru (3), Os(4))

To a solution of the corresponding chlorido complex [(Cym)MCl($\kappa^2 S, P$ -H₂L1)][SbF₆] (0.17 mmol) in acetone (10 mL), 65.9 mg (0.19 mmol) of AgSbF₆ were added. The resulting suspension was stirred for 2 h and kept for 3 days at -20 °C. The AgCl formed was separated with cannula and the filtrate was concentrated under reduced pressure to *ca*. 2 mL. The slow addition of *n*-pentane led to the precipitation of an orange (complex **3**) or yellow (complex **4**) solid, which was washed with *n*-pentane (3 × 5 mL) and vacuum-dried. Crystals of **4** suitable for X-ray diffraction analysis were obtained by crystallisation from CH₂Cl₂/*n*-hexane solutions.



Complex 3. Yield: 145.7 mg, (79 %). Anal. Calcd for $C_{32}H_{37}N_2F_{12}PRuSSb_2$: C, 35.4; H, 3.4; N, 2.6; S, 2.95. Found: C, 35.8; H, 3.7; N, 2.5; S, 2.8. HRMS (μ -TOF), $C_{32}H_{36}N_2PRuS$, [M – 2 SbF₆ – H]⁺, calcd: 613.1375, found: 613.1376. IR (cm⁻¹): v(NH) 3120-3415 (vbr), v(SbF₆) 652 (s). ¹H NMR (500.10 MHz, CD₂Cl₂, RT) δ = 8.20 (vbs, NH), 7.70-7.37 (m, 10H, PPh₂), 7.34 (A part of an AB system, 2H, H₂, H₆, *p*-Tolyl), 7.27 (B part of an AB system, *J*(A,B) = 7.9 Hz,

2H, H₃, H₅, *p*-Tolyl), 6.00, 5.97 (2 × bs, 2H, H_A, H_B), 5.78 (bd, 1H, H_B·), 5.49 (bd, J = 5.8 Hz, 1H, H_A·), 4.18 (dm, J = 38.6 Hz, 1H, NCH₂), 3.36 (m, 1H, NCH₂), 3.08, 2.61 (2 × m, 2H, PCH₂), 2.36 (s, 3H, Me *p*-Tolyl), 2.33 (m, 1H, CH *i*Pr), 1.80 (s, 3H, Me Cym), 1.21 (d, J = 7.1 Hz, 3H, Me *i*Pr), 1.15 (d, J = 7.0 Hz, 3H, Me *i*Pr). ¹³C{¹H} NMR (125.77 MHz, CD₂Cl₂, RT): $\delta = 187.29$ (C=S), 134.48-129.70 (PPh₂), 140.94 (CMe), 134.01 (CN), 131.39 (CH₃, CH₅), 123.42 (CH₂, CH₆) (*p*-Tolyl), 116.39 (*C*-Me, Cym), 105.19 (*C*-*i*Pr, Cym), 92.32 (CH_A·), 89.02 (CH_B·, CH_A, CH_B), 57.70 (CH₂N), 32.03 (CH *i*Pr), 25.27 (CH₂P), 23.22, 22.95 (Me *i*Pr), 21.83 (Me *p*-Tolyl), 18.47 (Me Cym). ³¹P{¹H} NMR (202.46 MHz, CD₂Cl₂, RT): $\delta = 60.81$ (bs).



Complex 4. Yield: 173.7 mg, (87 %). Anal. Calcd for $C_{32}H_{37}N_2F_{12}OsPSSb_2$: C, 32.7; H, 3.2; N, 2.4; S, 2.7. Found: C, 32.5; H, 3.2; N, 2.3; S, 2.6. HRMS (μ -TOF), $C_{32}H_{36}N_2OsPS$, [M – H – 2 SbF₆]⁺, calcd: 703.1945, found: 703.1938. IR (cm⁻¹): v(NH) 3080-3430 (vbr), v(SbF₆) 652 (s). ¹H NMR (500.10 MHz, CD₂Cl₂, RT): δ = 8.40 (bs, NH), 7.72-7.31(m, 10H, PPh₂), 7.43-7.29 (m, 4H, *p*-Tolyl), 6.14 (d, *J* = 5.9 Hz, 1H, H_A), 6.10 (d, *J* = 5.8 Hz, 1H, H_B), 6.04 (d, 1H, H_B), 5.67 (d, 1H, H_A·), 4.23 (dm, *J* = 36.6 Hz, 1H, NCH₂), 3.36 (m, 1H, NCH₂), 2.99, 2.67 (2 × m, 2H, PCH₂), 2.36 (s, 3H, Me *p*-Tolyl), 2.17 (m, 1H, CH *i*Pr), 1.89 (s, 3H, Me Cym), 1.21 (d, *J* = 7.0 Hz, 3H, Me *i*Pr), 1.15 (d, *J* = 7.0 Hz, 3H, Me *i*Pr). ¹³C{¹H} NMR (125.77 MHz, CD₂Cl₂, RT): δ = 191.09 (C=S), 142.00, 131.42 (CH₃, CH₅), 130.35, 123.15 (CH₂, CH₆) (*p*-Tolyl), 134.79-130.60, 133.40 (d, *J* = 58.3), 128.60 (d, *J* = 64.3) (PPh₂), 110.29 (*C*-Me, Cym), 99.59 (*C*-*i*Pr, Cym), 84.45, 84,41 (CH_B, CH_A·), 80.39 (CH_A), 76.32 (CH_B·), 61.48 (CH₂N),

31.48 (CH *i*Pr), 25.61 (d, J = 35.7, CH₂P), 23.23, 23.16 (Me *i*Pr), 21.86 (Me *p*-Tolyl), 18.32 (Me Cym). ³¹P{¹H} NMR (202.46 MHz, CD₂Cl₂, RT): $\delta = 26.96$ (s).

3 Kinetic studies for the H/D exchange at the Cym methyl protons of complex 7

Kinetic experiments were carried out in an NMR tube. Determination of observable kinetic constants were accomplished by ¹H NMR integration of the Me(Cym) hydrogens *versus* time, using the methyl groups, Me(*p*-Tolyl), as internal reference. Kinetic parameters (ΔH^{\ddagger} , ΔS^{\ddagger} , ΔG^{\ddagger}) were obtained through Eyring analysis; $\ln(k_{obs}/T) = -\Delta H^{\ddagger}/RT + \ln(k_B/h) + (\Delta S^{\ddagger}/R)$.



Kinetic experiment at 368 K: $[CymRu(\kappa^3P,N,N'-HL2)][SbF_6]$ (18.11 mM) in 0.35/0.10 mL of THF- d_8/D_2O



1[H] 50536 48509
50536 48509
48509
43317
42517
37604
60608
80423
96931
72203
42308
25347
87241
25294
19101
65923
25633



Kinetic experiment at 363 K: [CymRu(κ³*P*,*N*,*N*'-HL2)][SbF₆] (18.16 mM) in 0.35/0.10 mL of THF-*d*₈/D₂O

Kinetic experiment at 358 K: [CymRu(κ³*P*,*N*,*N*'-HL2)][SbF₆] (18.33 mM) in 0.35/0.10 mL of THF-*d*₈/D₂O





4 NMR and DFT studies on the fluxionality of the complexes 5, 6, 11 and 12

The variable temperature ³¹P{¹H} NMR spectra of complexes 5, 6, 11 and 12 (Fig. S1) indicate



that they are fluxional.

Fig. S1 Variable temperature ³¹P{¹H} NMR spectra (202.46 MHz, CD₂Cl₂)

For complex 5, analysis of the temperature evolution of the singlet recorded at 313 K gives an activation energy at the coalescence temperature of 9.50 ± 0.12 kcal·mol⁻¹. Additionally, below 193 K a new signal at about 61.4 ppm appeared. To account for these experimental data, the four rotamers depicted in Fig. S2 were considered (data taken from the crystal structure of complex 5). From DFT calculations, the energy barrier for the interconversions **5a1** \leftrightarrow **5a2**, **5b1** \leftrightarrow **5b2**, **5a1** \leftrightarrow **5b1** and **5a2** \leftrightarrow **5b2** are 6.4, 7.2, 10.3 and 11.1 kcal mol⁻¹, respectively (Fig. S3). The four isomers are unequally populated according to the relative Gibbs free energy values calculated that are quoted in Fig. S3. The calculated energy barrier for the rotation around the arene centroid-metal axis (6.4 and 7.2 kcal mol⁻¹) is close to the minimum value that allows achieve the required temperature to frozen the involved movement and, therefore, to detect by NMR spectroscopy the implicated individual species.^{S1}



Fig. S2 Schematic representation of the rotamers **5a1,2** and **5b1,2**. Dihedral angles (°): **5a1**, C(7)-Ct-Ru-P: 101.7, S-C(25)-N(2)-C(26): 158.6; **5a2**, C(7)-Ct-Ru-P: -50.1, S-C(25)-N(2)-C(26): 158.7; **5b1**, C(7)-Ct-Ru-P: 103.9, S-C(25)-N(2)-C(26): -8.4; **5b2**, C(7)-Ct-Ru-P: -46.1, S-C(25)-N(2)-C(26): -8.0. Ct stands for the centroid of the Cym ligand. For the atom labelling, see Fig. 1 in Results and Discussion section).



Fig. S3 Gibbs free energy profile of the equilibrium between isomers **5a1** and **5a2** (**A**), **5b1** and **5b2** (**B**), and rotamers **5a1** and **5b1** (**C**), **5a2** and **5b2** (**D**). For clarity, hydrogen atoms have been omitted, except the NH proton. Free energies are in kcal mol⁻¹.

(Fig. S3). The four isomers are unequally populated according to the relative Gibbs free energy values calculated that are quoted in Fig. S3. The calculated energy barrier for the rotation around the arene centroid-metal axis (6.4 and 7.2 kcal mol⁻¹) is close to the minimum value that

allows achieve the required temperature to frozen the involved movement and, therefore, to detect by NMR spectroscopy the implicated individual species.^{S1}

A plausible explanation is as follows: at the lowest temperature recorded, 173 K, only one of the two rotations around the arene centroid-metal axis processes considered (**5a1** \leftrightarrow **5a2** or **5b1** \leftrightarrow **5b2**) is fast. However, at this temperature, the other three exchange processes proposed should be essentially frozen. One of the three ³¹P{¹H} NMR singlets observed at 173 K can be assigned to the average of the two rotamers involved in the exchange active at this temperature. The two other ³¹P{¹H} NMR singlets can be attributed to each one of the two remaining rotamers that are in the slow exchange regime on the NMR time scale. Heating up to 193 K, rotation around the arene centroid-metal axis of both species becomes free and consequently from 193 K onwards, the ³¹P{¹H} NMR spectrum of the sample consists of only two singlets. At about 222 K these two singlets coalesce which gives an $\Delta G^{\#}$ value for the process at this temperature of 9.50 kcal mol⁻¹, in good agreement with the calculated values, 10.3 and 11.1 kcal mol⁻¹, for the rotation about the C(25)–N(2) bond. Above 222 K equilibration by rotation around this bond also becomes fast and, hence, the spectrum consists of a unique singlet.

Complex **6** shows comparable ${}^{31}P{}^{1}H$ NMR behaviour and similar activation energy at the coalescence temperature ($8.89 \pm 0.12 \text{ kcal} \cdot \text{mol}^{-1}$) than complex **5**. Therefore, probably, it undergoes a similar dynamic process in solution.

Evolution with temperature of the ${}^{31}P{}^{1}H$ NMR spectrum of complexes 11 and 12 (Fig. S1) follows a common pattern, characteristic of a two-site exchange process: one unique singlet at high temperature broadens, coalesces and splits into two singlets. The activation energies at the coalescence temperature are 10.16 ± 0.12 and 10.02 ± 0.12 kcal·mol⁻¹, for complexes 11 and 12, respectively.

To carry out DFT calculations, we have taken compound **2** as a model since its crystal structure has been determined by X-ray diffraction analysis (see Fig. S5, page S44) and, as in compounds **11** and **12**, in complex **2**, the phosphano-thiourea ligand coordinates to the metal forming a seven-membered metalacycle. As potentially responsible for the observed dynamic behaviour, a conformational change within the seven-membered metalacycle ($\mathbf{A} \leftrightarrow \mathbf{B}$) and an *s-cisoide* to *s-transoide* rotation around the C–N bond of the phosphano-thiourea ligand ($2\mathbf{a} \leftrightarrow 2\mathbf{b}$) were examined (Fig. S4).





2a, **2b**: Schematic representation of a selected fragment of two rotamers around the C–N bond of the phosphano-guanidino ligand in complex **2**.

Gibbs free energy profile for the equilibrium between **2a** and **2b**. For clarity, hydrogen atoms have been omitted, except the NH protons. Free energies are in kcal mol⁻¹.

The performed DFT calculations give a barrier of 8.9 kcal·mol⁻¹ for the interconversion from conformation **A** to conformation **B** and establish that conformer **B** is about 1.8 kcal·mol⁻¹ ¹ less stable than conformer **A**. The calculated energy barrier fits well the experimental value obtained by NMR spectroscopy (see above), but the 1/4, **B**/A population ratio, measured by ³¹P{¹H} NMR spectroscopy, is inconsistent with the calculated energy gap between the two conformers. On the other hand, an activation barrier of 12.5 kcal·mol⁻¹ for the **2a** \rightarrow **2b** interconversion and a Gibbs free energy difference between **2b** and **2a** of 1.7 kcal·mol⁻¹ was obtained. Again, the calculated energy barrier fits well the NMR experimental value obtained, but the population ratio measured by ${}^{31}P{}^{1}H$ NMR is not as expected for the calculated energy gap between the two rotamers. In summary, the theoretical calculations do not explain satisfactorily the fluxional process observed.

S1 J. K. Faller, *Comprehensive Organometallic Chemistry III*, Vol. 1. Eds.: R. H. Crabtree, D. M. P. Mingos, Elsevier, Oxford, 2007, p. 409.

5 NMR spectra of the ligand H₂L1 and of the complexes 1-6 and 11-19

* Denotes solvent

The spectra of the hydrido complexes **11-16** (Pages S25-S31) have been recorded under hydrogen pressure

¹H NMR of H₂L1 (500.10 MHz, CD₂Cl₂, RT)



7.8 7.6 7.4 7.2 7.0 6.8 6.6 6.4 6.2 6.0 5.8 5.6 5.4 5.2 5.0 4.8 4.6 4.4 4.2 4.0 3.8 3.6 3.4 3.2 3.0 2.8 2.6 2.4 2.2 f1 (ppm)

¹³C{¹H} NMR of H₂L1 (125.77 MHz, CD₂Cl₂, RT)





¹H NMR of [(Cym)RuCl(κ²*P*,*S*-H₂L1)][SbF₆] (1) (500.10 MHz, CD₂Cl₂, RT)



¹³C{¹H} NMR of [(Cym)RuCl(κ²P,S-H₂L1)][SbF₆] (1) (125.77 MHz, CD₂Cl₂, RT)



³¹P{¹H} NMR of [(Cym)RuCl(κ²P,S-H₂L1)][SbF₆] (1) (202.46 MHz, CD₂Cl₂, RT)



³¹P{¹H} NMR of [(Cym)RuCl(κ²P,S-H₂L1)][SbF₆] (1) (202.46 MHz, CD₂Cl₂, 173 K)

30 20 f1 (ppm) 10

0

-10

-20

-30

100

90

80

70

60

50

40





¹³C{¹H} NMR of [(Cym)OsCl(κ²*P*,*S*-H₂L1)][SbF₆] (2) (125.77 MHz, CD₂Cl₂, 193K)



³¹P{¹H} NMR of [(Cym)OsCl(κ²P,S-H₂L1)][SbF₆] (2) (202.46 MHz, CD₂Cl₂, 193K)



¹H NMR of [(Cym)Ru(κ³P,N,S-H₂L1)][SbF₆]₂ (3) (500.10 MHz, CD₂Cl₂, RT)





³¹P{¹H} NMR of [(Cym)Ru(κ³P,N,S-H₂L1)][SbF₆]₂ (3) (202.46 MHz, CD₂Cl₂, RT)





¹H NMR of [(Cym)Os(κ³P,N,S-H₂L1)][SbF₆]₂ (4) (500.10 MHz, CD₂Cl₂, RT)

¹³C{¹H} NMR of [(Cym)Os(κ³P,N,S-H₂L1)][SbF₆]₂ (4) (125.77 MHz, CD₂Cl₂, RT)



³¹P{¹H} NMR of [(Cym)Os(κ³P,N,S-H₂L1)][SbF₆]₂ (4) (202.46 MHz, CD₂Cl₂, RT)



f1 (ppm) . 19

¹H NMR of [(Cym)Ru(κ³P,N,S-HL1)][SbF₆] (5) (500.10 MHz, CD₂Cl₂, RT)



¹³C{¹H} NMR of [(Cym)Ru(κ³P,N,S-HL1)][SbF₆] (5) (125.77 MHz, CD₂Cl₂, RT)



³¹P{¹H} NMR of [(Cym)Ru(κ³P,N,S-HL1)][SbF₆] (5) (202.46 MHz, CD₂Cl₂, RT)



³¹P{¹H} NMR of [(Cym)Ru(κ³P,N,S-HL1)][SbF₆] (5) (202.46 MHz, CD₂Cl₂, 173 K)



¹H NMR of [(Cym)Os(κ³P,N,S-HL1)][SbF₆] (6) (500.10 MHz, CD₂Cl₂, RT)



52 50 48 46 44 42 40 38 36 34 32 30 28 26 24 22 20 18 16 14 12 10 8 6 4 2 0 -2 -4 -6 -8 -10 fl(ppm)



¹H NMR of [(Cym)RuH(κ²P,S-H₂L1)][SbF₆] (11) (500.10 MHz, THF-d₈, RT)



¹³C{¹H} NMR of [(Cym)RuH(κ²P,S-H₂L1)][SbF₆] (11) (125.77 MHz, THF-d₈, RT)









¹H NMR of [(Cym)OsH(κ²P,S-H₂L1)][SbF₆] (12) (500.10 MHz, THF-d₈, RT)



¹³C{¹H} NMR of [(Cym)OsH(κ²P,S-H₂L1)][SbF₆] (12) (125.77 MHz, THF-*d*₈, RT)



³¹P{¹H} NMR of [(Cym)OsH(κ²P,S-H₂L1)][SbF₆]₂ (12) (202.46 MHz, THF-*d*₈, RT)



³¹P{¹H} NMR of [(Cym)OsH(κ²P,S-H₂L1)][SbF₆]₂ (12) (202.46 MHz, THF-*d*₈, 193K)



¹H NMR of [(Cym)RuH(κ²P,N-H₂L2)][SbF₆] (13) (500.10 MHz, THF-d₈, RT)



¹³C{¹H} NMR of [(Cym)RuH(κ²P,N-H₂L2)][SbF₆] (13) (125.77 MHz, THF-d₈, RT)



³¹P{¹H} NMR of [(Cym)RuH(κ²P,N-H₂L2)][SbF₆]₂ (13) (202.46 MHz, THF-*d*₈, RT)



¹H NMR of [(Cym)OsH(κ²P,N-H₂L2)][SbF₆] (14) (500.10 MHz, CD₂Cl₂, RT)



¹³C{¹H} NMR of [(Cym)OsH(κ²P,N-H₂L2)][SbF₆] (14) (125.77 MHz, CD₂Cl₂, RT)



³¹P{¹H} NMR of [(Cym)OsH(κ²P,N-H₂L2)][SbF₆]₂ (14) (202.46 MHz, CD₂Cl₂, RT)



¹H NMR of [(Cym)RuH(κ²N,N'-H₂L3)][SbF₆] (15) (500.10 MHz, THF-d₈, RT)



¹³C{¹H} NMR of [(Cym)RuH(κ²N,N'-H₂L3)][SbF₆] (15) (125.77 MHz, THF-d₈, RT)





¹³C{¹H} NMR of [(Cym)OsH(κ²N,N'-H₂L3)][SbF₆] (16) (125.77 MHz, THF-*d*₈, RT)





¹³C{¹H} NMR of [(Cym)Ru(κ³N,N',C-H₂L3_{-H})][SbF₆] (17) (125.77 MHz, CD₃OD, RT)



¹H NMR of [(Cym)Os(κ³N,N',C-H₂L3_{-H})][SbF₆] (18) (500.10 MHz, CD₃OD, RT)



¹³C{¹H} NMR of [(Cym)Os(κ³N,N',C-H₂L3_{-H})][SbF₆] (18) (125.77 MHz, CD₃OD, RT)



¹H NMR of complex 19 (500.10 MHz, THF-d₈, RT)

Isolated from the catalytic hydrogenation



¹H NMR of 19 (500.10 MHz, CD₂Cl₂, RT)

Prepared from complex 9 and methyl acrylate



¹³C{¹H} of complex 19 (500.10 MHz, CD₂Cl₂, RT) Prepared from complex 9 and methyl acrylate



6 Catalytic hydrogenation essays

Table S1 Hydrogenation of methyl acrylate^a



Entry	Catalyst	t (h)	Conv. (%) ^b
1		7	100
2		30	91
3		7	100
4		216	71
5		8	99
6		216	72

^{*a*}Reaction conditions: catalyst 0.015 mmol (5 mol %), methyl acrylate (0.30 mmol), H₂ (5 bar), internal reference 1,3,5-trimethoxybenzene (0.03 mol), in 0.45 mL of THF-d⁸. ^{*b*}Based on 1,3,5-trimethoxybenzene. Determined by NMR. Table S2 Hydrogenation of unsatutared substrates^a



^{*a*}Reaction conditions: catalyst 0.015 mmol (5 mol %), substrate (0.30 mmol), H₂ (5 bar), internal reference 1,3,5-trimethoxybenzene (0.03 mol) in 0.45 mL of THF-d⁸. ^{*b*}Based on 1,3,5-trimethoxybenzene. Determined by NMR.

Table S3 Hydrogenation of acrylates^a

		0	8 0-t D ¹	0 .C.	
	R ¹	\sim C $OR^4 + H_2$ $-$	$rac{cat}{90^{\circ}C}$ R^2	°OR⁴ R ³	
	R ⁴	R ³			Com
Entry	(mol%)	Substrate	Product	t	$(\%)^b$
1	5	Q	Q	7	100
2 ^c 3 ^d	1			30 26	100
4 ^e	0.1	OMe	/ OMe	116	91
5	5		O U OEt	10	98
6	5	O II C OfBu	O II O <i>t</i> Bu	5	100
7	5			5	100
8	5		O I C OMe	72	90
9	5	O U OEt	O II C OEt	45	67
10	5	O II C OMe	O II C OMe	144	14

^aReaction conditions: catalyst 0.015 mmol (5 mol %), substrate (0.30 mmol), H₂ (5 bar), internal reference 1,3,5-trimethoxybenzene (0.03 mol), in 0.45 mL of THF-d8. bBased on 1,3,5-trimethoxybenzene. Determined by NMR. cCatalyst 0.003 mmol (1 mol %), methyl acrylate (0.30 mmol). dCatalyst 0.003 mmol (1 mol %), methyl acrylate (0.30 mmol) in 0.45 mL of D₂O. eCatalyst 0.0015 mmol (0.1 mol %), methyl acrylate (1.50 mmol) in 0.45 mL of D_2O .



7 X-ray crystallography

X-ray diffraction data were collected on a Smart APEX (4, 6), APEX DUO (2, 5, 17) or D8 VENTURE (13, 19) Bruker diffractometers, using graphite-monochromated Mo $\kappa\alpha$ radiation $(\lambda = 0.71073 \text{ Å})$. Single crystals were mounted on a fiber or a micromount, coated with a protecting perfluoropolyether oil and cooled to 100(2) K (complexes 2, 4, 5, 13, 17, 19) or 150 K (compound 7) with an open-flow nitrogen gas. Data were collected using ω -scans (and φ scans for 13 and 19) and narrow oscillation frame strategies. Diffracted intensities were integrated and corrected for absorption effects by using multi-scan method using SAINT^{S2} and SADABS^{S3} programs, included in APEX2 or APEX4 (for 13 and 19) packages. Structures were solved by Patterson or direct methods with SHELXS^{S4} and refined by full-matrix least squares on F² with SHELXL program^{S5} included in Wingx program system^{S6} or OLEX2 program.^{S7} Although hydrogen atoms have been observed in Fourier difference maps, most of them have been included in the model in calculated positions and refined with a riding model. The NH hydrogen atoms have been included in calculated positions and refined with a riding model (complexes 4, 5, 13, 14 and 19), or included in observed positions, and refined with geometrical restrains in N-H bond lengths (compound 17) with isotropic displacement parameters restrained to be 1.2 times the Ueq of their N parent atoms (compound 2 and 6). The presence of hydride ligand in isostructural 13 and 14 has been evidenced by NMR of the crystals of complex 14. Hydride positions have been determined with HYDEX program^{S8} and kept fixed. Further details about specific problems encountered in data reduction or structure refinement (disorder or solvent modelling) are described below.

Structural data for 2: $C_{32}H_{37}ClF_6N_2OsPSSb$; $M_r = 974.06$; orange prism, $0.075 \times 0.085 \times 0.150 \text{ mm}^3$; triclinic P^{-1} ; a = 10.3781(9) Å, b = 10.4833(9) Å, c = 16.9677(15) Å; $a = 97.1740(10)^{\circ}$, $\beta = 103.529(2)^{\circ}$, $\gamma = 99.2620(10)^{\circ}$; V = 1745.8(3) Å³, Z = 2, $D_c = 1.853$ g/cm³; $\mu = 4.649$ cm⁻¹; min. and max. absorption correction factors: 0.590 and 0.845, $2\theta_{\text{max}} = 60.494^{\circ}$;

17326 reflections measured, 8271 unique; $R_{int} = 0.0549$; number of data/restraint/parameters 8271/2/416; $R_1 = 0.0371$ [6087 ref. with $I > 2\sigma(I)$], w $R(F^2) = 0.0706$ (all data); largest difference peak 1.918 e·Å⁻³. During the data collection the crystal fell from the top of the glass fiber. Another crystal was mounted and therefore two sets of data were then measured. Both were corrected from absoprtion and scale with SORTAV program.^{S9} The sample forms prismatic crystals mutually stuck and weakly diffracting. Selected crystals were selected as indexation processes were successful. However, at the end of the data treatment completeness was not achieved for this triclinic structure.

Structural data for 4: $C_{32}H_{36}F_{12}N_2OsPSSb_2 \cdot C_6H_{14} \cdot 5(H_2O) \cdot 0.5(CH_2Cl_2)$; Mr = 1371.11; yellow plate, $0.070 \times 0.095 \times 0.150 \text{ mm}^3$; triclinic P^{1} ; a = 10.1759(6) Å, b = 15.2630(8) Å, c = 15.4343(8) Å; $\alpha = 86.7350(10)^{\circ}$, $\beta = 80.2470(10)^{\circ}$, $\gamma = 81.2590(10)^{\circ}$; V = 2333.9(2) Å³, Z = 2, Dc = 1.951 g/cm³; $\mu = 4.087$ cm⁻¹; min. and max. absorption correction factors: 0.5885 and 0.7278, 2θ max = 56.952°; 26736 reflections measured, 10801 unique; Rint = 0.0443; number of data/restraint/parameters 10801/0/473; RI = 0.0503 [8824 ref. with $I > 2\sigma(I)$], wR(F2) = 0.1013 (all data); largest difference peak 1.720 e·Å⁻³. Asymmetric unit contains solvent, including a water molecule interacting with a NH fragment. The rest of the solvent has been found to be highly disordered, its inclusion in the structural model leads to unrealistic geometrical parameters. The contribution of this solvent to diffracted intensity has been calculated with a solvent mask.

Structural data for 5: $C_{32}H_{36}F_6N_2PRuSSb\cdot CH_4O$; Mr = 880.54; yellow prism, 0.140 × 0.150 × 0.150 mm³; monoclinic $P2_1/n$; a = 9.0786(5) Å, b = 21.1970(12) Å, c = 18.2541(10) Å; $\beta = 97.1700(10)^{\circ}$; V = 3485.3(3) Å³, Z = 4, Dc = 1.686 g/cm³; $\mu = 1.374$ cm⁻¹; min. and max. absorption correction factors: 0.8074 and 0.8620, 2θ max = 52.182°; 46641 reflections measured, 7072 unique; Rint = 0.0332; number of data/restraint/parameters 7072/13/388; RI = 0.0638 [5829 ref. with $I > 2\sigma(I)$], wR(F2) = 0.1604 (all data); largest difference peak 3.514 e·Å⁻

³. A dynamic disordered has been observed in four fluorine atoms of the counterion. It has been modelled with three sets of positions, and refined with geometrical restraints and a common isotropic displacement parameter. Furthermore, *p*-cymene and part of tridentate ligand have been found to be disordered. Involved atoms have been included in the model in two sets of positions with complementary occupancy factors.

Some unsuccessful tests have been performed in order to model residual density peaks as solvent. Solvent contribution to calculated structure factors has been calculated with a solvent mask procedure included in OLEX2.

Structural data for 6: $C_{32}H_{36}F_6N_2POsSSb \cdot 0.5(C_5H_{12})$; Mr = 973.68; yellow needle, $0.060 \times 0.070 \times 0.300 \text{ mm}^3$; monoclinic $P2_I/n$; a = 9.1041(8) Å, b = 21.3312(16) Å, c = 18.2996(14) Å; $\beta = 96.8650(10)^{\circ}$; V = 3528.3(5) Å³, Z = 4, $Dc = 1.833 \text{ g/cm}^3$; $\mu = 4.527 \text{ cm}^{-1}$; min. and max. absorption correction factors: 0.4637 and 0.6257, 2θ max = 56.568° ; 23365 reflections measured, 8078 unique; Rint = 0.0719; number of data/restraint/parameters 8078/7/398; R1 = 0.0751 [5272 ref. with $I > 2\sigma(I)$], wR(F2) = 0.1643 (all data); largest difference peak $1.539 \text{ e} \cdot \text{Å}^{-3}$. A dynamic disordered has been observed in four fluorine atoms of the counterion. It has been modelled with two sets of positions, and isotropically refined. Some unsuccessful tests have been performed in order to model residual density peaks as solvent (pentane). Solvent contribution to calculated structure factors has been calculated with SQUEEZE program.^{S10}

Structural data for 13: $C_{39}H_{44.93}Cl_{0.07}F_6N_3PRuSb \cdot C_{39}H_{44.96}Cl_{0.04}F_6N_3PRuSb$; Mr = 1851.01; yellow prism, $0.066 \times 0.080 \times 0.180 \text{ mm}^3$; monoclinic $P2_1/c$; a = 27.2956(12) Å, b = 11.7168(5)Å, c = 24.4621(11) Å; $\beta = 92.768(2)^\circ$; V = 7814.3(6) Å³, Z = 4, $Dc = 1.573 \text{ g/cm}^3$; $\mu = 1.183$ cm⁻¹; min. and max. absorption correction factors: 0.6912 and 0.7457, 2θ max = 56.362°; 224868 reflections measured, 19415 unique; *Rint* = 0.0312; number of data/restraint/parameters 19415/200/1001; RI = 0.0303 [18295 ref. with $I > 2\sigma(I)$], wR(F2) = 0.0686 (all data); largest difference peak 1.933 e·Å⁻³. Asymmetric unit contains two independent molecules. Both cations exhibit a disorder between coordinated hydride or chloride ligand. For each one, the H/Cl ratio had been refined with complementary occupancy factors. A SbF₆ counterion has also been found to be disordered, concerned atoms have been included in the model in two sets of positions and refined with restrains in geometry and atomic displacement parameters.

Structural data for 14: $C_{39}H_{44.85}Cl_{0.15}F_6N_3OsPSb \cdot C_{39}H_{44.70}Cl_{0.30}F_6N_3OsPSb ; <math>Mr = 2040.98$; yellow prism, $0.083 \times 0.140 \times 0.180 \text{ mm}^3$; monoclinic $P2_I/c$; a = 27.612(4) Å, b = 11.6966(18)Å, c = 24.349(4) Å; $\beta = 94.223(4)^{\circ}$; V = 7843(2) Å³, Z = 4, $Dc = 1.729 \text{ g/cm}^3$; $\mu = 4.042 \text{ cm}^{-1}$; min. and max. absorption correction factors: 0.5153 and 0.6655, 2θ max = 57.378°; 324467 reflections measured, 19814 unique; *Rint* = 0.0396; number of data/restraint/parameters 19814/18/1079; R1 = 0.0322 [18902 ref. with $I > 2\sigma(I)$], wR(F2) = 0.0744 (all data); largest difference peak 1.933 e·Å⁻³. Asymmetric unit contains two independent molecules. Both cations exhibit a disorder between coordinated hydride or chloride ligand. For each one, the H/Cl ratio had been refined with complementary occupancy factors. A SbF₆ counterion and a p-cymene fragment have also been found to be disordered, concerned atoms have been included in the model in two sets of positions and refined with restrains in geometry and atomic displacement parameters.

Structural data for 17: $C_{31}H_{35}F_6N_4RuSb \cdot C_4H_{10}O$; Mr = 874.57; yellow plate, $0.140 \times 0.200 \times 0.420 \text{ mm}^3$; triclinic $P^{\overline{1}}$; a = 10.3597(5) Å, b = 16.0888(18) Å, c = 21.7237(11) Å; $a = 85.2910(10)^0$, $\beta = 80.1320(10)^0$, $\gamma = 87.9280(10)^0$; V = 3554.3(3) Å³, Z = 4, Dc = 1.634 g/cm³; $\mu = 1.250 \text{ cm}^{-1}$; min. and max. absorption correction factors: 0.6842 and 0.7902, 2θ max = 60.558° ; 60272 reflections measured, 19504 unique; Rint = 0.0214; number of data/restraint/parameters 19504/2/800; RI = 0.0348 [16831 ref. with $I > 2\sigma(I)$], wR(F2) = 0.0839 (all data); largest difference peak 1.623 e · Å -³. One of the counterions has been found to be disordered. Involved atoms have been modelled with two sets of positions. Solvent

(diethylether) contribution to calculated structure factors has been calculated with SQUEEZE program.

Structural data for 19: $C_{35}H_{41}F_6N_4O_2RuSb \cdot C_4H_8O$; Mr = 958.64; yellow plate, $0.055 \times 0.075 \times 0.120 \text{ mm}^3$; orthorhombic $P2_12_12_1$; a = 11.6436(8) Å, b = 15.5640(11) Å, c = 21.8392(15) Å; V = 3957.7(5) Å³, Z = 4, $Dc = 1.609 \text{ g/cm}^3$; $\mu = 1.134 \text{ cm}^{-1}$; min. and max. absorption correction factors: 0.5833 and 0.7457, 2θ max = 56.604°; 52333 reflections measured, 9779 unique; *Rint* = 0.0651; number of data/restraint/parameters 9779/0/493; RI = 0.0411 [7702 ref. with $I > 2\sigma(I)$], wR(F2) = 0.0983 (all data); largest difference peak 0.890 e·Å⁻³.

- S3 (a) R. H. Blessing, Acta Crystallogr., 1995, A51, 33-38. (b) SADABS, Area Detector Absorption Correction Program, Bruker AXS, Madison, WI, 1996.
- S4 (a) G. M. Sheldrick, *Acta Crystallogr.*, 1990, A46, 467-473. (b) G. M. Sheldrick, *Acta Crystallogr.*, A short history of SHELX. 2008, A64, 112-122.
- S5 G. M. Sheldrick, Acta Crystallogr., 2015, C71, 3-8.
- S6 L. J. Farrugia, Acta Crystallogr., 2012, 45, 849-854.
- S7 O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. Howard and H. Puschmann, *J App. Cryst.*, 2009, **42**, 339-341.
- S8 A. G. Orpen, J. Chem. Soc., Dalton Trans., 1980, 2509-2516.
- S9 R. H. Blessing, Crystallogr. Rev., 1987, 2, 3-58.
- S10 A. L. Spek, Acta Crystallogr. C, 2015, 71, 9-18.

S2 SAINT+, *version 6.01: Area-Detector Integration Software*, Bruker AXS, Madison, WI, **2001**.

8 Molecular structures of complexes 2, 4, 6 and 14

Crystal structure of complex 2



Fig. S5 Molecular structure of the cation of the complex **2**. For clarity all the hydrogen atoms are omitted, except those of NH groups.

Os-Ct ^a	1.7183(2)	S(1)-Os-P(1)	91.77(4)
Os-Cl	2.4101(13)	CI-Os-S(1)	89.69(5)
Os-S(1)	2.4308(13)	CI-Os-P(1)	86.18(4)
Os-P(1)	2.3345(12)	P(1)-Os-S(1)	91.77(4)
Ct-Os-Cl	123.23(1)	Os-S(1)-C(25)	117.74(18)
Ct-Os-S(1)	122.79(1)	N(1)-C(25)	1.329(6)
Ct-Os-P(1)	131.15(1)	N(2)-C(25)	1.333(6)
aCt is the controld of the ring of the Cym ligand			

Table S4 Selected bond lengths (Å) and angles (°) for complex 2 $\ensuremath{\mathsf{2}}$

^aCt is the centroid of the ring of the Cym ligand

Crystal structure of complex 4



Fig. S6 Molecular structure of the cation of the complex 4. For clarity all the hydrogen atoms are omitted, except those of NH groups.

Os-Ct ^a	1.7188(1)	S(1)-Os-N(1)	68.21(14)
Os-S(1)	2.4014(18)	P(1)-Os-N(1)	81.59(14)
Os-P(1)	2.3072(16)	Os-S(1)-C(25)	83.4(2)
Os-N(1)	2.179(5)	S(1)-C(25)-N(1)	110.0(4)
Ct-Os-S(1)	130.62(1)	Os-N(1)-C(25)	97.7(4)
Ct-Os-P(1)	133.70(1)	N(1)-C(25)	1.449(8)
Ct-Os-N(1)	134.25(1)	N(2)-C(25)	1.293(8)
S(1)-Os-P(1)	85.31(6)		
aCt is the contraid of the ring of the Cym ligand			

Table S5 Selected bond lengths (Å) and angles (°) for complex ${\bf 4}$

^aCt is the centroid of the ring of the Cym ligand

Crystal structure of complex 6



Fig. S7 Molecular structure of the cation of the complex 6. For clarity all the hydrogen atoms are omitted, except that of NH bond.

complex o .			
Os-Ct ^a	1.7068(1)	Os-S(1)-C(25)	81.9(5)
Os-S(1)	2.401(3)	S-C(25)-N(1)	106.5(9)
Os-P(1)	2.317(3)	S-C(25)-N(2)	126.3(11)
Os-N(1)	2.078(11)	N(1)-C(25)-N(2)	127.2(12)
Ct-Os-S(1)	129.43(1)	Os-N(1)-C(24)	124.1(8)
Ct-Os-P(1)	132.42(1)	Os-N(1)-C(25)	104.5(8)
Ct-Os-N(1)	135.10(1)	C(24)-N(1)-C(25)	118.4(12)
S(1)-Os-P(1)	94.50(10)	N(1)-C(25)	1.353(16)
S(1)-Os-N(1)	66.5(3)	N(2)-C(25)	1.349(16)
P(1)-Os-N(1)	73.5(3)		

Table S6. Selected bond lengths (Å) and angles (°) for complex **6**.

^aCt is the centroid of the ring of the Cym ligand.

Table S7Selected bond lengths (Å) andangles (°) for the second independentcation of complex13parameters for the first independentcation are collected in Figure 3 caption)

M Ct(1)a	1 7450(1)
	1.7439(1)
M-P(1)	2.2617(6)
M-N(1)	2.1135(18)
M-H(1A)	1.527
Ct(1)-M-P(1)	134.69(1)
Ct(1)-M-N(1)	127.78(1)
Ct(1)-M-H(1)	129
P(1)-M-N(1)	81.57(5)
P(1)-M-H(1)	91.2
N(1)-M-H(1)	68.6
M-N(1)-C(25)	124.70(16)
N(1)-C(25)-N(2)	118.4(2)
N(1)-C(25)-N(3)	122.0(2)
N(2)-C(25)-N(3)	119.6(2)
N(1)-C(25)	1.309(3)
N(2)-C(25)	1.419(3)
N(3)-C(25)	1.369(3)

^aCt is the centroid of the ring of the Cym ligand.

Crystal structure of complex 14



Fig. S8 Molecular structure of one of the chemically equivalent but crystallographically independent cations of the complex **14**. For clarity all the hydrogen atoms are omitted (except hydrido and those of NH bonds) together with minor components of disordered fragments have been omitted.

	Cation 1	Cation 2
M-Ct(1) ^a	1.7219(3)	1.7549(3)
M-P(1)	2.2909(9)	2.2783(10)
M-N(1)	2.127(3)	2.119(3)
M-H(1A)	1.605	1.606
Ct(1)-M-P(1)	133.58(1)	136.11(1)
Ct(1)-M-N(1)	129.82(1)	126.94(1)
Ct(1)-M-H(1)	121	124
P(1)-M-N(1)	80.80(8)	80.93(9)
P(1)-M-H(1)	87.9	84.6
N(1)-M-H(1)	89.2	89.0
M-N(1)-C(25)	125.4(2)	125.2(3)
N(1)-C(25)-N(2)	119.3(3)	118.8(4)
N(1)-C(25)-N(3)	122.0(3)	121.8(4)
N(2)-C(25)-N(3)	118.7(3)	119.4(4)
N(1)-C(25)	1.308(4)	1.308(5)
N(2)-C(25)	1.355(4)	1.356(5)
N(3)-C(25)	1.368(5)	1.366(5)
-		

Table S8	Selected bond lengths (Å) and angles (2)
for comple	x 14	

^aCt is the centroid of the ring of the Cym ligand.

Table S9Selected boangles (°) for the seccationofcomplex	ond lengths (Å) and cond independent 17 (structural
parameters for the	first independent
cation are collected in	Figure 5 caption)
	Cation
Ru-Ct ^a	1.7136(1)
Ru-N(1)	2.0912(19)
Ru-N(2)	2.0833(19)
Ru-C(19)	2.065(2)
Ct-Ru-N(1)	128.14(1)
Ct-Ru-N(2)	132.74(1)
Ct-Ru-C(19)	128.10(1)
N(1)-Ru-N(2)	75.95(8)
N(1)-Ru-C(19)	90.17(8)
N(2)-Ru-C(19)	84.45(8)
N(2)-C(17)	1.305(3)
N(3)-C(17)	1.357(3)
N(4)-C(17)	1.371(3)

^aCt is the centroid of the ring of the Cym ligand

9 DFT calculations

Computational details

DFT geometry optimizations and thermochemical calculations were carried out with the Gaussian 09 program package,^{S11} using the B3LYP-D3 dispersion-corrected hybrid functional.^{S12} Geometry optimizations were performed in solution using the continuum SMD model, ^{S13} with dichloromethane ($\varepsilon = 8.93$) as solvent in the fluxionality studies of complexes 2 and 5, or tetrahydrofuran ($\varepsilon = 7.4257$) in the reaction pathways of 7. Basis sets used were the LanL2TZ(f) effective core potential basis set for the transition metal atoms, and the 6-311G(d,p) basis set for the remaining ones. The LanL2TZ(f) basis set is based in the Hay-Wadt relativistic effective core potentials (RECPs) for the transition metal atoms.^{S14} All minima (no imaginary frequencies) and transition states (one imaginary frequency) were characterized by calculating the Hessian matrix. ZPE and gas-phase thermal corrections (entropy and enthalpy, 298.15 K, 1 atm) from these analyses were calculated. The transition state search was performed with a relaxed PES scan of the key geometrical parameter and then the highest energy structure was optimized as a transition state by the default Gaussian 09 algorithms. The chemical correctness of the transition states found were confirmed by visual inspection of the normal mode having a negative vibrational frequency, followed by moving the TS geometries along the reaction path using the GaussView program utilities and reoptimizing to verify the nature of the products.

S11 Gaussian 09 (Revision D.01): Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.: Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. A.; Nakatsuji, H.; Caricato, M.; Li, X.; Hratchian, H. P.; Izmaylov, A. F.; Bloino, J.; Zheng, G.; Sonnenberg, J. L.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; Montgomery, J. A. Jr.; Peralta, J. E.; Ogliaro, F.; Bearpark, M.; Heyd, J. J.; Brothers, E.; Kudin, K. N.; Staroverov, V. N.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, A.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam, J. M.; Klene, M.; Knox, J. E.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Zakrzewski, V. G.; Voth, G. A.: Salvador, P.; Dannenberg, J. J.;

Dapprich, S.; Daniels, A. D.; Farkas, Ö.; Foresman, J. B.; Ortiz, J. V.; Cioslowski, J.; Fox, D. J. Gaussian, Inc., Wallingford CT, 2009.

- (a) C. Lee, W. Yang and R. G. Parr, *Phys. Rev. B*, 1988, **37**, 785-789. (b) A. D. Becke, *J. Chem. Phys.*, 1993, **98**, 1372-1377. (c) A. D. Becke, *J. Chem. Phys.*, 1993, **98**, 5648-5652. (d) S. Grimme, J. Antony, S. Ehrlich and H. Krieg, *J. Chem. Phys.*, 2010, **132**, 154104.
- S13 S. A. V. Marenich, C. J. Cramer and D. G. Truhlar, J. Phys. Chem. B, 2009, 113, 6378.
- S14 L. E. Roy, P. J. Hay, R: L. Martin, J. Chem. Theory Comput., 2008, 132, 1029-1031.